First peptides

BPC-157 for beginners

BPC-157 is a lab-made peptide. It is not FDA-approved. Promise Peptides prescribes now. U.S. patients only. A licensed U.S. provider reviews each request and decides. Not everyone qualifies. Availability varies by state and treatment. Compounded medicines are not FDA-approved.Visit Promise Peptides for BPC-157. Neo may earn money when readers become Promise patients.

5 min read. Updated 8 October 2026.

The short version

BPC-157 is a peptide made in a lab. It is a chain of fifteen amino acids, the small building blocks that proteins are made from. Its design copies part of a larger protein found in human stomach juice.

Almost all of the research on BPC-157 has been done in rats and other animals. Only a handful of very small studies have looked at people, and none was the kind of large, careful trial that can show whether a medicine works or is safe.

BPC-157 is not an FDA-approved medicine. Online, it is mostly sold with a "research use only" label, which means no one reviews your health before it is sold.

What BPC-157 is

The name is short for "body protection compound". Scientists also call it a stable gastric pentadecapeptide. That sounds harder than it is: gastric means to do with the stomach, and pentadecapeptide means a peptide fifteen amino acids long.

Although it is modelled on a stomach protein, BPC-157 itself is made in a lab. It is not known to be something your body makes and carries around on its own.

Where the research stands

Most BPC-157 studies are preclinical, which means they were done in animals or in cells in a dish, before any testing in people. Researchers have studied it in rats with injured tendons, stomach ulcers and other lab injuries. An animal study is where research starts, not evidence of what happens in a person.

A few examples show what that research looks like:

A 2003 study used rats with a cut Achilles tendon (the tendon at the back of the ankle). It did not test a treatment in people.
Researchers have studied whether it affects angiogenesis, the growth of new small blood vessels, in animals.
A 2022 study in rats and dogs tracked what happens to BPC-157 in the body. It was broken down into small fragments very quickly.

The human evidence is thin. A 2025 review found only three small pilot studies in people. One gave it through a drip to two healthy adults to look for safety problems. Another followed twelve women with a painful bladder condition. A third described a group of people with knee pain. None of the three compared treated people with a similar group who did not get it, which is the basic check a trial needs.

Much of the early research also came from one research group, and newer reviewers note that few unrelated labs have repeated it.

Where BPC-157 stands with the FDA

BPC-157 is not FDA-approved for any use. The FDA has also named it in warning letters to online sellers as an unapproved drug.

The rest of its FDA story is about compounding, which is when a pharmacy makes a medicine to order for one patient from a prescription. The FDA keeps lists of the raw ingredients pharmacies ask to use:

In September 2023, the FDA placed BPC-157 in its "category 2", the group of ingredients where it had found possible significant safety risks.
On the FDA's page current as of April 22, 2026, BPC-157 is no longer in the category 2 table. It is shown as "nominated but withdrawn", because the groups that had asked the FDA to consider it took their requests back. The FDA's safety concerns are still printed beside it.
A withdrawn request is not an approval, and it is not a clearance.
On July 23 and 24, 2026, an FDA advisory committee met in public with BPC-157 on its agenda. Before the meeting, FDA staff had proposed against listing it. The FDA had published no record of the committee's votes as of September 2026.

BPC-157 is also banned in sport at all times, under the anti-doping rule for substances not approved as medicines anywhere.

What a prescription route looks like

A licensed route starts with a person, not a product. A licensed clinician asks about your health history, your other medicines and any conditions, then decides whether anything fits you at all. The answer can be no. If something is prescribed, a licensed pharmacy decides separately whether it can lawfully prepare it, and a prescription does not guarantee that it will. A compounded preparation is not FDA-approved.

A research-only seller works differently. The vial is sold for lab research and labelled not for human use. No one reviews your health, and it is hard to know what the vial really contains. A prescription does not make BPC-157 approved or change the research above. It means someone qualified has looked at your case.

What is not known

Whether it helps people. The large, controlled human trials that would answer this do not exist.
Long-term safety. No one has followed large groups of people over time, so the balance of benefit and risk in humans is genuinely unknown.
Growth signals. Because animal studies link BPC-157 to new blood-vessel growth, and tumours also rely on new blood vessels, researchers raise a theoretical concern for anyone with an active or suspected cancer. This comes from how it works, not from human studies.
Other medicines. In rats it changed how the brain handles serotonin, a chemical messenger. That raises an untested question about medicines that affect serotonin, such as some antidepressants.
Pregnancy, breastfeeding and children. It has not been studied in any of these groups.

Talking to a licensed clinician about BPC-157

Promise Peptides is a U.S. telehealth platform. Promise prescribes peptides now through licensed U.S. providers. A licensed U.S. provider reviews every request and your health history, then decides whether to prescribe. Not everyone qualifies, and the answer can be no. Prescribed medicines are prepared by licensed U.S. compounding pharmacies. Each pharmacy separately decides whether it can lawfully prepare a prescription; a prescription does not guarantee it will be filled. Compounded medicines are not FDA-approved. BPC-157 appears in the FDA’s "nominated but withdrawn" table. Its safety concerns remain; withdrawal is not clearance, approval or placement in Category 1. How Neo is paid for sets out the rest. U.S. patients only. Availability varies by state and by treatment. Promise is LegitScript-certified. That certification is not FDA approval.

Visit Promise Peptides for BPC-157

Neo may earn money when readers become Promise patients.